Home
LEXX
LEXX News

Latest Lexaria Bioscience Corp. (LEXX) News on September 7, 2025

MT Newswires

2 months ago

Lexaria Bioscience Secures 2 Patents in Australia, Japan

LEXX: GLP-1-H25-5 Study Complete

Zacks Small Cap Research

3 months ago

LEXX: GLP-1-H25-5 Study Complete

Lexaria Bioscience announces completion of GLP-1-H25-5 study

TipRanks

3 months ago

Lexaria Bioscience announces completion of GLP-1-H25-5 study

ACCESS Newswire

3 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

ACCESS Newswire

3 months ago

Lexaria Attending BIO International Convention

ACCESS Newswire

4 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

NewMediaWire

4 months ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

NewMediaWire

4 months ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

LEXX: Second Quarter Results

Zacks Small Cap Research

4 months ago

LEXX: Second Quarter Results

ACCESS Newswire

4 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully

Simply Wall St.

5 months ago

We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully

ACCESS Newswire

5 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

ACCESS Newswire

5 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

ACCESS Newswire

6 months ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

ACCESS Newswire

6 months ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

ACCESS Newswire

6 months ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

ACCESS Newswire

7 months ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

ACCESS Newswire

7 months ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

ACCESS Newswire

7 months ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

ACCESS Newswire

7 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

ACCESS Newswire

7 months ago

Lexaria Releases Annual Letter from the CEO

LEXX: IRB Approval Clears Way for GLP-1 Study #5

Zacks Small Cap Research

7 months ago

LEXX: IRB Approval Clears Way for GLP-1 Study #5

MT Newswires

8 months ago

Lexaria Bioscience Receives Ethics Board Approval for Oral Liraglutide Pilot Study

ACCESS Newswire

8 months ago

Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

MT Newswires

8 months ago

Lexaria Bioscience Says Oral DehydraTECH-Tirzepatide Causes Fewer Adverse Effects

ACCESS Newswire

8 months ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

8 months ago

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Lexaria's Registered GLP-1 Study #4 Begins Dosing

ACCESSWIRE

9 months ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

ACCESSWIRE

9 months ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

ACCESSWIRE

9 months ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide

TipRanks

9 months ago

Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

ACCESSWIRE

9 months ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

LEXX: Phase I Start Imminent

Zacks Small Cap Research

9 months ago

LEXX: Phase I Start Imminent

Newsfile

9 months ago

BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals

Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

9 months ago

Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

ACCESSWIRE

9 months ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ACCESSWIRE

9 months ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study

ACCESSWIRE

10 months ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

ACCESSWIRE

10 months ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

MT Newswires

10 months ago

Lexaria Bioscience Gets Ethics Board Approval to Begin Dosing in Phase 1b Diabetes, Weight Loss Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

ACCESSWIRE

10 months ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

ACCESSWIRE

10 months ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

ACCESSWIRE

10 months ago

Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study

ACCESSWIRE

a year ago

Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

a year ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth

Simply Wall St.

a year ago

Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth

MT Newswires

a year ago

Lexaria Bioscience Expects to Raise $5 Million in Registered Direct Offering

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

a year ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

MT Newswires

a year ago

Lexaria Bioscience Launches Human Study of DehydraTECH-Processed Tirzepatide

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

ACCESSWIRE

a year ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Lexaria Updates Current GLP-1 Market

ACCESSWIRE

a year ago

Lexaria Updates Current GLP-1 Market

MT Newswires

a year ago

Lexaria Bioscience Names Michael Shankman CFO

Lexaria Appoints Michael Shankman as Chief Financial Officer

ACCESSWIRE

a year ago

Lexaria Appoints Michael Shankman as Chief Financial Officer

MT Newswires

a year ago

Lexaria Bioscience Receives Approval From Independent Review Board for Pilot Study of Tirzepatide

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

ACCESSWIRE

a year ago

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

Zacks Small Cap Research

a year ago

LEXX: Changing Gears: Christopher Takes Over as CEO

MT Newswires

a year ago

Lexaria Bioscience Taps InVivo Therapeutics CFO Richard Christopher As New CEO

Lexaria Releases Strategic Letter from the Outgoing CEO

ACCESSWIRE

a year ago

Lexaria Releases Strategic Letter from the Outgoing CEO

Lexaria Welcomes Industry Veteran as New CEO

ACCESSWIRE

a year ago

Lexaria Welcomes Industry Veteran as New CEO

ACCESSWIRE

a year ago

Lexaria Enters a Material Transfer Agreement for DehydraTECH Research

MT Newswires

a year ago

Lexaria Bioscience Says Its Second Weight Loss Drug Human Study Showed No Adverse Events

ACCESSWIRE

a year ago

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

First Results from Lexaria's Second GLP-1 Human Pilot Study

MT Newswires

a year ago

Lexaria Bioscience Says Liraglutide 'Outperforming' Semaglutide in Animal Weight Loss Study

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

ACCESSWIRE

a year ago

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

MT Newswires

a year ago

Lexaria Bioscience Reports Blood Sugar Reductions in Ongoing Diabetes Study; Shares Fall

Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

ACCESSWIRE

a year ago

Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Results from Lexaria's Molecular Characterization Study

ACCESSWIRE

a year ago

Positive Results from Lexaria's Molecular Characterization Study

LEXX: GLP-1 Agonist Program Updates

Zacks Small Cap Research

a year ago

LEXX: GLP-1 Agonist Program Updates

Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

ACCESSWIRE

a year ago

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Lexaria Preparing For Strategic Growth

ACCESSWIRE

a year ago

Lexaria Preparing For Strategic Growth

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study

MT Newswires

a year ago

Lexaria Bioscience Secures New Antiviral Drug Delivery, Epilepsy Patents

Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy

ACCESSWIRE

a year ago

Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy

MT Newswires

a year ago

Lexaria Bioscience Hires Contract Research Organization For 12-week Study

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

ACCESSWIRE

a year ago

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

MT Newswires

a year ago

Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study

Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study

Lexaria Awards Contract For Third GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

Lexaria Awards Contract For Third GLP-1 Human Pilot Study

MT Newswires

a year ago

Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise

Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy

ACCESSWIRE

a year ago

Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy

Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study

ACCESSWIRE

a year ago

Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study

Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation

Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study

Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs

ACCESSWIRE

a year ago

Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance

ACCESSWIRE

a year ago

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance

LEXX: Begin with the End in Mind

Zacks Small Cap Research

a year ago

LEXX: Begin with the End in Mind

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

ACCESSWIRE

a year ago

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Lexaria Awarded New Patents

ACCESSWIRE

a year ago

Lexaria Awarded New Patents

Newsfile

a year ago

Lexaria to Present at The LD Micro Invitational XIV

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

ACCESSWIRE

a year ago

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

ACCESSWIRE

a year ago

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

ACCESSWIRE

2 years ago

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study

ACCESSWIRE

2 years ago

7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study

Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

ACCESSWIRE

2 years ago

Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year

Simply Wall St.

2 years ago

This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year

Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

2 years ago

Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

2 years ago

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria's Submits Investigational New Drug Application

ACCESSWIRE

2 years ago

Lexaria's Submits Investigational New Drug Application

Share on Social Networks: